Page 2 - Nasdaq Acad News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $37.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 117.01% from […]

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They presently have a $37.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 118.16% from the company’s current price. […]

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They presently have a $37.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 118.16% from the stock’s […]

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) shares hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $16.60 and last traded at $16.74, with a volume of 1475997 shares traded. The stock had previously closed at $16.99. Wall Street Analyst Weigh In ACAD has been the […]

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report)’s stock price reached a new 52-week low during trading on Tuesday . The stock traded as low as $16.60 and last traded at $16.74, with a volume of 1475997 shares. The stock had previously closed at $16.99. Analyst Ratings Changes A number of analysts recently issued reports […]